Cilengitide trifluoroacetate

For research use only. Not for use in humans.

目录号：S7077 别名： EMD 121974, NSC 707544 中文名称：三氟醋酸盐西仑吉肽

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂，作用于αvβ3受体和αvβ5受体，无细胞试验中IC50分别为4.1 nM和79 nM，比作用于gpIIbIIIa选择性高10倍左右。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3718.02 现货
RMB 2212.59 现货
RMB 8108.38 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Cilengitide trifluoroacetate发表文献42篇：

产品安全说明书

Integrin抑制剂选择性比较

生物活性

产品描述 Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂，作用于αvβ3受体和αvβ5受体，无细胞试验中IC50分别为4.1 nM和79 nM，比作用于gpIIbIIIa选择性高10倍左右。Phase 2。
靶点
αvβ3 receptor [1]
(Cell-free assay)		 αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
体外研究

Cilengitide是一种环化五胜肽类肽，争夺精氨酸-甘氨酸-天冬氨酸（RGD）肽序列。调节整合素-配体结合。Cilengitide选择性且有效抑制αvβ3和αvβ5整合素与基质蛋白结合，如Vitronectin, Fibronectin, Fibrinogen, von Willebrand Factor, Osteopontin, 及其他。[1]10 μM Cilengitide完全抑制BAE，BME和HUVE细胞与Vitronectin 和 Fibronectin附着。Cilengitide在体外作用于三维胶原蛋白和血纤维蛋白凝胶使用FGF-2(或 VEGF-A)预处理的BAE细胞，抑制血管生成，IC50分别为15 μM 和8 μM, 4 μM 和 3 μM。[2]Cilengitide 抑制细胞增殖，诱导内皮细胞凋亡，且诱导人体内皮前体细胞分化。50 μg/mL Cilengitide完全抑制人体微血管内皮细胞系HMEC-1增殖，导致〜30%细胞发生细胞凋亡。[3]1 μM Cilengitide处理9天，抑制近40%EPCs增殖。1 μM Cilengitide处理14天，抑制80%以上EPCs 分化。[4]Cilengitide抑制粘附，诱导肿瘤细胞凋亡。25 μg/mL Cilengitide使60%以上的DAOY细胞(髓母细胞瘤)和U87MG细胞(胶质母细胞瘤) 与Vitronectin 和 Tenascin分离。25 μg/mL Cilengitide诱导细胞凋亡率将近50% 。[5]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
G28 MlHjSpVv[3Srb36gRZN{[Xl? M3zpd|UxKM7:Zz;tcC=> NFi0eXg{OC94MD:xNlAhdWmw MlfDbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGZCUyxiU4LjJIFv\CCDa4S= MkLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1  M{LLRmZ2dmO2aX;uJGF{e2G7 MXSyNE81OC94MDFOwIcwdWx? MlLvbY5pcWKrdIOgSmFMKGGwZDDTdoPDqA>? M{XpdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
G44 NGP4UYNCeG:ydH;zbZMhSXO|YYm= M3ftUlEwPS93MDFOwIcwdWx? NFe4RXUzPCCq MWXpcoR2[2W|IHHwc5B1d3Orcx?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G28 MWrBdI9xfG:|aYOgRZN{[Xl? MlfoNU82NzVyIN88[{9udA>? MYWyOEBp NYLySYdZcW6mdXPld{BieG:ydH;zbZM> NVTtWYN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
G44 NVqySnI4WHKxbHnm[ZJifGmxbjDBd5NigQ>? MmPBNU82NzVyIN88[{9udA>? NYjL[nQ{OjRxNEivO|IhcA>? MUjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGXo[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 NE[0d5FRem:uaX\ldoF1cW:wIFHzd4F6 NXnMUYNXOS93L{WwJO69\y:vbB?= M3rYe|I1NzR6L{eyJIg> MXTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1XjUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1  MWrBdI9xfG:|aYOgRZN{[Xl? MWWxM|UwPTBizsznM41t MUmyOEBp Mmr6bY5lfWOnczDhdI9xfG:|aYO= MnL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1  NYroRZRsWHKxbHnm[ZJifGmxbjDBd5NigQ>? NUGzNpZ{OS93L{WwJO69\y:vbB?= NHjsN2gzPC92OD:3NkBp M3vKSolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NV[5T2tyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1  NW\Ne45GTnWwY4Tpc44hSXO|YYm= M4DiOFEwPS93MDFOwIcwdWx? NXX6V21GOjRiaB?= NEKxPWZqdmS3Y3XzJIEh\G:|ZTDk[ZBmdmSnboSg[IV1[WOqbXXueOKh NV\mSYxZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
LNT-229  MWHGeY5kfGmxbjDBd5NigQ>? M4rMN|AvOS9zL{GwJO69VQ>? NX;Mfo9kOjRiaB?= NXKyWFRNcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO|E9N2F-
T98G M4DFSWZ2dmO2aX;uJGF{e2G7 NHXoTYgxNjFxMT:xNEDPxE1? M1jjSlI1KGh? M3:2eIlueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYfUV4t6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
LN-18 Ml\YSpVv[3Srb36gRZN{[Xl? MlHDNE4yNzFxMUCg{txO NF7TSmMzPCCq MnG2bY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3HPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
LN-308 NX7SW4JlTnWwY4Tpc44hSXO|YYm= NV;3UXZJOC5zL{GvNVAh|ryP MWqyOEBp NVLIdnNJcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
U87MG M3T4[GZ2dmO2aX;uJGF{e2G7 NUTG[5hlOC5zL{GvNVAh|ryP MnHkNlQhcA>? MkKwbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVHoRZd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
U87  NGLub4JHfW6ldHnvckBCe3OjeR?= M4r3eVAuOjVizsznM41N NVSyU25OOTJiaNMg M2HwSYlv\HWlZYOgZZV1d3CqYXf5JIRwe2ViZHXw[Y5l\W62bIm= NHf5UJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U251 NITBS5hHfW6ldHnvckBCe3OjeR?= M33BXlAuOjVizsznM41N MV6xNkBpyqB? NUjRW5JmcW6mdXPld{BifXSxcHjh[5kh\G:|ZTDk[ZBmdmSnboTsfS=> M1;0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U87  MYTBdI9xfG:|aYOgRZN{[Xl? MXOyOUDPxGdxbVy= NHK5V|QzPC92ODDo MlTsbY5lfWOnczDhdI9xfG:|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6 NVLhdWplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U251 NEjqOpJCeG:ydH;zbZMhSXO|YYm= M3rKZlI2KM7:Zz;tUC=> MoHsNlQwPDhiaB?= NWe2eZh7cW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7 NYqzfnliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U87  NV7B[3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Md2MxNTJ3IN88[{9uVA>? MmDTNE01QCCq NYLX[JpjcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N|Q{RC:jPh?=
U251 NInNPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fRbFAuOjVizsznM41N MXewMVQ5KGh? NGHkUWVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NWfVT2xGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U251MG NIrT[5pCeG:ydH;zbZMhSXO|YYm= NXfRVoRJOSEEtV2= NF3MXGs1QCCq NGnVW|lqdmS3Y3XzJIFxd3C2b4Ppdy=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEiwO{c,OjN|NUS4NFc9N2F-
U87MG NXP3T3FtSXCxcITvd4l{KEG|c3H5 M3i0[FEhyrWP M2r6R|Q5KGh? M{flfYlv\HWlZYOgZZBweHSxc3nz M3r4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U251MG Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhRZoxNTJ3IN88US=> MonZNlQwPDhiaB?= NFHrTpJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEiwO{c,OjN|NUS4NFc9N2F-
U87MG NYfx[G9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Gb3AxNTJ3IN88US=> MkTvNlQwPDhiaB?= Ml;abY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NEXGfo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1OFgxPyd-MkOzOVQ5ODd:L3G+
MCF-7  NWjobmNiSXCxcITvd4l{KEG|c3H5 NWPy[3A{OC1{MDFOwG0> M4nWOFQ5KGh? NGDnWllqdmS3Y3XzJIFxd3C2b4Ppdy=> NUfWWFZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
T-47D NXj5WZZoSXCxcITvd4l{KEG|c3H5 NWTHepM5OC1{MDFOwG0> NFLjR4M1QCCq NUHUWWpQcW6mdXPld{BieG:ydH;zbZM> M4G5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N|ExOjxxYU6=
MCF-7  MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHaOokxNTJyIN88US=> NYmw[5JVQTZiaB?= NX64XXdScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4DIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N|ExOjxxYU6=
T-47D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL5NE0zOCEQvF2= MkjUPVYhcA>? NETHSoZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVjvfo5URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
FaDu  MmO0RZBweHSxc3nzJGF{e2G7 NGru[XkzPcLiwsXNxsA> M1HNb|Q5yqCqwrC= NHu3SXlqdmS3Y3XzJIFxd3C2b4Ppdy=> MoDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
CAL27 MnjORZBweHSxc3nzJGF{e2G7 Ml\zNlXDqML3TdMg MXy0POKhcMLi NXPMdoU1cW6mdXPld{BieG:ydH;zbZM> NIPUd4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
SCC25 Mm\NRZBweHSxc3nzJGF{e2G7 NUDpNnRHOjYEoNM1UeKh NHmwSlU1QMLiaNMg MXLpcoR2[2W|IHHwc5B1d3Orcx?= M4XxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW3NFU3Lz5{NEW1O|A2PjxxYU6=
FaDu  M3jQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOwOk4zPeLCk{KwNOKhyrWP NID1NpQ4OiCq NHXOd|Nz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= M4HKdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW3NFU3Lz5{NEW1O|A2PjxxYU6=
CAL27 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrNOk4zPeLCk{KwNOKhyrWP Mkj6O|IhcA>? NWToOlJtemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= NF;lVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
SCC25 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjTZY0zPi5{NfMAl|IxOMLiwsXN NV;xXIVZPzJiaB?= NXSxPGlsemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= NXfmTJhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
H28 MlvuR4VtdCCYaXHibYxqfHliQYPzZZk> Mnn3NUBvVS1{MECg{txO MVq3NkBp MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4DmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
MM05 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVuxJI5ONTJyMDFOwG0> NXzhOHZmPzJiaB?= MVfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHu3NXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MSTO-211H MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHHWbWwyKG6PLUKwNEDPxE1? M17LTlczKGh? NUX0fYFn\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NITzNGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
REN Mn76R4VtdCCYaXHibYxqfHliQYPzZZk> MlrqNUBvVS1{MECg{txO MUK3NkBp NGP2NIZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3fXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
LN-308  MUTGeY5kfGmxbjDBd5NigQ>? MVSxNQKBkc7:bR?= M4LCflI1KGh? M2C1V2ROW00EoB?= M2\6XZJm\HWlZYOgRYhTKHC{b4TlbY4hdGW4ZXzzJIFv\CCGUlWgdoVxd3K2ZYKgZYN1cX[rdIm= MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
HaCaT  Moq4SpVv[3Srb36gRZN{[Xl? MWqxNQKBkc7:bR?= NWHPdoF6PDhiaB?= Mn\wSG1UV8Li Mm\odoVlfWOnczDUS2Yu|rJ{wrDtVm5CKGW6cILld5Nqd25? M3z2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
S-24 NXjhd2RyTnWwY4Tpc44hSXO|YYm= NFrqdY0yNzFy4pEJ{txu Mlr4NlQhcA>? M3[5fGROW00EoB?= NX7lSnhtemWmdXPld{BFWkVicnXwc5J1\XJiYXP0bZZqfHl? M3voO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
ZH-161 M{DYR2Z2dmO2aX;uJGF{e2G7 NXzmfFdUOS9zMPMAje69dQ>? M4m3XFI1KGh? M3LUSWROW00EoB?= MljidoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJk> Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
LN-308  NYT3VXU4TnWwY4Tpc44hSXO|YYm= M3K1bVEwOTBxMUCw5qCK|ryv MWWyOEBp NWWwOGUxTE2VT9Mg M4i1U5Jm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NEjGeVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
M21 NEL1SnJHfW6ldHnvckBie3OjeR?= MljiNUBpeg>? NIWye3NDcW6maX7nJIFn\mmwaYT5JJRwKGmwdHXndolvKGGucHjhek9j\XSjMzDo[ZRmem:maX3ldkBqdiCqdX3hckBOOjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBqdnSnZ4Lpck1u\WSrYYTl[EBpfW2jbjDNNlEh[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAyKGi{IHnuJJBz\XOnbnPlJI9nKE2wQ3yyMEBKSzVyIE2gNE4xODB2IN88UU4> NFO0R2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1N|gyPCd-Mk[3OVM5OTR:L3G+
HEK293T NXvPe2gyTnWwY4Tpc44h[XO|YYm= NWrOe2FNOiCqcoO= NF\Gc|ZDcW6maX7nJIFn\mmwaYT5JJRwKHOxbIXicIUhfHK3bnPheIVlKGi3bXHuJJJm[2:vYnnuZY51KE[lLYTh[4dm\CCjbIDoZXZj\XSjMzDhcoQhcW62ZXfybY5{KHencnWg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgZYZ1\XJiMjDodpMh[nliY3;tdIV1cXSrb36gSWxKW0FvbHnr[UBie3OjeTygTWM2OCB;IECuNFAxPTFizszNMi=> NEPWVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVA6Pid-MkSwPVUxQTZ:L3G+
HT-29 NV:zdZJnTnWwY4Tpc44h[XO|YYm= NWrFfndkOiCqcoO= NELpd|lCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHnueIVoemmwIHHsdIhiXmKndHG1JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiWLUK5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJIFlcGW|aX;uJJRwKH[rdILvcoVkfGmwIHHmeIVzKDJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MUW5OEc,Ojh|NUG1PVQ9N2F-
HEK293 NEC3V5hHfW6ldHnvckBie3OjeR?= M1vIdlIhcHK| Mon6RY51[WexbnnzeEBi[3Srdnn0fUBifCCrboTl[5JqdiCjbIDoZXZj\XSjMzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygZYRp\XOrb36geI8h\mmkcnnuc4dmdiCjZoTldkAzKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ{IN88UU4> M4TmZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
SKOV3 NYXITFdxTnWwY4Tpc44h[XO|YYm= NYTLRmxUOiCqcoO= NV\ZO4xQSW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThN4FteGijVnLleIE2KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPLU3Y{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKGGmaHXzbY9vKHSxIH\pZpJqdm:pZX6gZYZ1\XJiMjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6zO{DPxE1w NFruPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NVU6PCd-MkizOVE2QTR:L3G+
U87MG M2XzUWZ2dmO2aX;uJIF{e2G7 Mn70NVAxKG6P NHS1VpozPCCqcoO= NYXHOI86UW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBxPTNiYXPjeY12dGG2aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> NXSyc21tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG M13afmZ2dmO2aX;uJIF{e2G7 NVTsVXRiOTByIH7N NHLHNGUzPCCqcoO= MVzJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bi[2O3bYXsZZRqd25iYYSgNVAxKG6PIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NIjzVW1HfW6ldHnvckBie3OjeR?= NX2ybYR6OTByIH7N NUDITZN5OjRiaILz M3fjSmlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGGlY4XteYxifGmxbjDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG MkfzSpVv[3Srb36gZZN{[Xl? MnnkNVAxKG6P MY[4JIhzew>? M2rFO2lvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gUWROOiCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFghcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIFv\CCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IGLUMXBEWiCvZYToc4Q> MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NEW2botHfW6ldHnvckBie3OjeR?= NV7MeHZOOTByIH7N NH;1W5YzPCCqcoO= MVXJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGDVUWEhdVKQQTDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>? MoXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NXrQO3lsTnWwY4Tpc44h[XO|YYm= NIPjVXcyODBibl2= M4XNOlI1KGi{cx?= Mk[1TY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIJ6KFKWLWDDVkBu\XSqb3S= M17sXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NG\6e3hHfW6ldHnvckBie3OjeR?= MVexNFAhdk1? MXOyOEBpenN? NHS0UFFKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l NIG5[lA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG MV7GeY5kfGmxbjDhd5NigQ>? MlnPNVAxKG6P MkLNNlQhcHK| NETac4ZKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[W6mIF3EUVQhcW6qaXLpeI9zKFOMLUG3NlI2PTBiYomgVnQuWEOUIH3leIhw\A>? NVT2S2RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG Ml[1SpVv[3Srb36gZZN{[Xl? M1PWUlExOCCwTR?= MnfnNlQhcHK| M3jUTmlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFIyKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHL5JHJVNVCFUjDt[ZRpd2R? NUH5ZZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NVi1NYRKSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1zueVExOCCwTR?= MWe3NkBpenN? M3jlbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZZQhOTByIH7NJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDifUBOXFNiYYPzZZk> NYPoNWgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG MlHxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlLWNVAxKG6P M2TXZlczKGi{cx?= Mkj1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczDheEAyODBibl2gZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KE2WUzDhd5NigQ>? NHz2dFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG Ml\SR4VtdCCleXPs[UBie3OjeR?= NFrHcVEyODBibl2= M3n4T|I1KGi{cx?= M4TqfWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDheEAyODBibl2gZYZ1\XJiMkSgbJJ{ MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG MU\BcpRqNWmwdnHzbZZmKGG|c3H5 MVmxNEB2VQ>? MmfoNlQhcHK| M2HjbWFvfGlvaX72ZZNqfmViYXP0bZZqfHliaX6gbJVu[W5iVUi3UWch[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IITyZY5{f2WubDDhd5NigQ>? NGiy[2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG NWH6XZhjSW62aT3pcpZie2m4ZTDhd5NigQ>? MWCxNEB2VQ>? Mnj3NlQhcHK| NF2xTFVCdnSrLXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSC2cnHud5dmdGxiYYPzZZk> NWCxeWFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
体内研究 Cilengitide单独处理，有效对抗肿瘤生长和血管生成。100 μg Cilengitide处理肿瘤，与对照组相比，显著降低CD31+血管数。100 μg Cilengitide处理动物大脑中的肿瘤，与接收无效肽处理的相比，促进细胞凋亡。Cilengitide 处理携带黑色素移植瘤M21的小鼠，对照组相比，延长小鼠寿命，分别为36.5 天vs 17.3天。[5]Cilengitide 可以增加细胞毒性药物相关联的治疗的益处，包括对肿瘤模型的化疗和放射治疗。Cilengitide (250 mg/dose)单独处理小鼠，与未经处理的小鼠相比，没有改变乳腺癌移植瘤的肿瘤生长，但与RIT（CMRIT）联合治疗，使用RIT和六种剂量的Cilengitide (250 mg/dose)增加治疗的疗效，小鼠的治愈率从只用RIT处理的 15%提高到53％。CMRIT处理内皮细胞5天，显著促进肿瘤细胞凋亡，且降低肿瘤细胞增殖。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[2]
- 合并

整合素竞争结合实验:

固定化重组可溶性的整合素，同时加入在Tris 缓冲生理盐水(TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4)中连续稀释的肽，及生物素化的Vitronectin（1μg/mL）。在37°C下温育3小时后，使用Tris 缓冲生理盐水洗涤，通过与抗生物素的碱性磷酸酶联合的抗体温育，再经对硝基苯基磷酸酶底物显影，测定结合的配体。加入NaOH终止反应，在405 nm处读取彩色信号强度。
细胞实验：[3]
- 合并
  • Cell lines: 人体微血管内皮细胞系HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 天
  • Method: HMEC-1 按每孔1×104个接种在未包被的48孔板中，在含4% FCS 及 Cilengitide的培养基中温育。在37°C下温育72小时, 用胰蛋白酶处理细胞并计数。
    (Only for Reference)
动物实验：[5]
- 合并
  • Animal Models: 携带人体胶质母细胞瘤移植瘤U87 MG的小鼠
  • Dosages: 100μg
  • Administration: 每天腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 702.68
化学式

C29H41F3N8O9
CAS号 199807-35-7
储存条件 粉状
溶于溶剂
别名 EMD 121974, NSC 707544

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • 回答：

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • 问题 2：

    Is Cilengitide a TFA salt?

  • 回答：

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Selleck产品目录册

Integrin Signaling Pathway Map
Tags: 购买Cilengitide trifluoroacetate | Cilengitide trifluoroacetate供应商 | 采购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate价格 | Cilengitide trifluoroacetate生产 | 订购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID